The financing provides $5M in immediate cash for the Phase 3 trial but loads the balance sheet with $10M in secured obligations exceeding market cap. The monthly redemption feature ($250K/month starting Dec 2026) creates cash drain risk. Monitor for any covenant breaches or delisting notices (trigger events) that could accelerate repayment at 115% of outstanding. The non-convertible preferred avoids common dilution but the 8% PIK feature could expand the preferred overhang.
Price Chart
Executive Summary
Imunon entered into a $10M financing with Streeterville Capital, consisting of $2.5M from 250 shares of non-convertible Series A Preferred Stock and $7.5M from two secured promissory notes (A-1 Note: $2.72M principal, 8% interest; B Note: $5M principal, 5% interest), both maturing in 18 months. $5M of the proceeds is held as cash collateral in a subsidiary account, leaving $5M immediately available for the Phase 3 OVATION 3 trial. The structure avoids common-stock dilution but adds secured debt and restrictive covenants, including a 10% prepayment premium and monthly redemption rights starting at month 6.
Key Financial Metrics
Key Facts
- Gross proceeds of $10M: $2.5M from 250 Series A Preferred shares at $10,000/share, $2.72M A-1 Note (net $2.5M after $200K OID and $20K expenses), $5M B Note.
- A-1 Note: 8% interest, 18-month maturity, $250K/month redemption starting month 6, plus limited redemptions at 5% of daily volume when stock trades 15% above Nasdaq Minimum Price.
- B Note: 5% interest, 18-month maturity, $5M held as cash collateral in a subsidiary account; can be exchanged for A Notes in $1M increments as A Notes or Preferred are reduced.
- Notes secured by substantially all assets except IP, guaranteed by subsidiaries CLSN Labs and IMNN Holdings.
- Preferred Stock: $12,000 stated value, 8% annual return (payable in cash or PIK shares), non-convertible, no voting rights, redeemable at 110% of liquidation amount at company option.
- Restrictive covenants: no additional debt or variable-rate issuances without investor consent, no fundamental transactions without approval, no asset sales or reverse splits without consent.
- Placement agent fee: 7% of gross proceeds ($700,000).
- Company market cap ~$9M; total debt-like obligation of $10M exceeds market cap.
Financial Impact
Total debt-like obligation of $10M (notes + preferred stated value) against a ~$9M market cap. Net immediate cash to company: $5M (after $5M collateralized). Effective interest cost: 8% on A-1 Note, 5% on B Note, plus 8% preferred return on $2.5M, plus 10% prepayment premium and 7% placement fee.
Risk Factors
- Total obligations ($10M) exceed market cap (~$9M), creating severe balance sheet risk.
- Monthly redemptions of $250K starting month 6 could strain cash if trial enrollment doesn't progress as expected.
- Restrictive covenants limit future financing flexibility and give Streeterville veto power over fundamental transactions.
- Delisting risk (Nasdaq minimum bid) is a trigger event that could force accelerated repayment at penalty rates.
- Placement agent fee of $700K (7%) is high for this structure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-027201 |
| Exhibit: ex3-1.htm | 0001493152-26-027201 |
| Exhibit: ex10-2.htm | 0001493152-26-027201 |
| Exhibit: ex10-3.htm | 0001493152-26-027201 |
| Exhibit: ex99-1.htm | 0001493152-26-027201 |
| Document: form8-k.htm | 0001493152-26-027201 |
| Document: 0001493152-26-027201-index-headers.html | 0001493152-26-027201 |
| Document: 0001493152-26-027201-index.html | 0001493152-26-027201 |
| Document: 0001493152-26-027201.txt | 0001493152-26-027201 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | S-1 | $1.22 | awaiting T+5 | — | $0.9100 (+25.41%) |
Oct 27, 2026 today | 8-K | $1.25 | awaiting T+5 | — | $0.9100 (−27.20%) |
Oct 21, 2026 6d ago | 8-K | $1.19 | awaiting T+5 | — | $0.9100 (−23.53%) |
Sep 29, 2026 28d ago | 8-K | $1.34 $1.12 | ▲ +16.10% | ▲ +18.05% | $0.9100 (+31.84%) |
Aug 11, 2026 10w ago | 8-K | $1.61 $1.58 | ▼ −1.86% | ▼ −1.42% | $0.9100 (−43.48%) |
Aug 11, 2026 11w ago | 8-K | $1.61 $1.58 | ▼ −1.86% | ▼ −1.46% | $0.9100 (−43.48%) |
Jun 30, 2026 16w ago | 8-K | $1.88 $1.95 | ▲ +3.72% | ▲ +3.46% | $0.9100 (−51.60%) |
Jun 16, 2026 18w ago | 8-K | $1.86 $1.73 | ▼ −6.99% | ▼ −5.95% | $0.9100 (−51.08%) |
Jun 4, 2026 20w ago | 8-K | $2.10 $2.03 | ▲ +3.33% | ▲ +0.78% | $0.9100 (+56.67%) |
May 12, 2026 24w ago | 8-K | $2.70 $2.26 | ▼ −16.30% | ▼ −16.37% | $0.9100 (−66.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers